James DArecca - 16 May 2025 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP, Chief Financial Officer
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca
Issuer symbol
HAE
Transactions as of
16 May 2025
Transactions value $
$0
Form type
4
Filing time
20 May 2025, 17:14:18 UTC
Previous filing
19 May 2025
Next filing
03 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DArecca James EVP, Chief Financial Officer 125 SUMMER STREET, BOSTON /s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca 20 May 2025 0001583903

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +7.11K +47.97% 21.9K 16 May 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +15.4K $0.00 15.4K 16 May 2025 Common Stock 15.4K $70.31 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3 This number includes unvested RSUs previously reported.
F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.